Valion Bio AI Stock Analysis
Want to see VBIO full AI Analyst Report?
Valion Bio (VBIO) AI Stock Analysis
Valion Bio
(NASDAQ:VBIO)
Overall score reflects heavy ongoing losses and cash burn despite a low-debt balance sheet and some early revenue traction. The stock’s technical setup is strongly bearish with price far below key moving averages, while valuation signals are limited due to negative earnings and no dividend. Recent financings help liquidity but come with dilution/structure and leadership-change risks.
Valion Bio (VBIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.90M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.18
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 52
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Valion Bio Business Overview & Revenue Model
Company Description
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Ne...
Valion Bio Earnings Call Summary
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the third quarter of 2025, Tivic Health Systems reported significant progress in its strategic transformation towards the biopharmaceutical market, having licensed entolimod and related assets to pivot from bioelectronics to biologic pharmaceuticals. The company is focusing on entolimod as a military countermeasure for acute radiation syndrome (ARS) and has moved forward with transferring two INDs related to ARS and advanced cancer. Financially, Tivic saw revenue net of returns at $140,000 for the quarter, an increase from $126,000 in the previous year, although nine-month revenue decreased to $302,000 from $600,000 due to reduced advertising spend. The cost of sales rose to $291,000, influenced by a $230,000 inventory reserve, while gross margins excluding this reserve improved to 42% from 35%. Operating expenses increased to $2,300,000 from $1,500,000 due to heightened R&D investments and corporate costs. The net loss widened to $2,600,000 from $1,400,000, and cash reserves grew to $3,500,000, supported by additional financing tranches totaling $3,800,000 during the quarter.
Valion Bio Financial Statement Overview
Summary
Mixed fundamentals: TTM revenue improved to ~$1.6M with positive gross profit (~39% gross margin), and the balance sheet shows very low debt (~$0.4M) versus equity (~$21.8M). However, profitability is deeply negative (EBIT/EBITDA roughly -6x revenue; net margin ~-7x) and cash burn remains material (TTM operating and free cash flow about -$5.5M), raising ongoing funding/dilution risk.
Income Statement
22NegativeBalance Sheet
70PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2024 | Dec 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 412.00K | 0 | 1.18M | 0 | 1.84M | 1.26M |
| Gross Profit | -331.00K | 0 | 287.00K | -352.00K | 299.00K | -46.00K |
| EBITDA | -7.06M | -7.84M | -8.06M | -4.06M | -9.92M | -5.61M |
| Net Income | -7.51M | -8.88M | -8.24M | -5.66M | -10.10M | -8.49M |
Balance Sheet | ||||||
| Total Assets | 6.23M | 31.61M | 5.16M | 2.81M | 5.88M | 15.04M |
| Cash, Cash Equivalents and Short-Term Investments | 3.45M | 12.64M | 3.40M | 2.00M | 3.52M | 12.97M |
| Total Debt | 0 | 6.45M | 369.00K | 0 | 530.00K | 708.00K |
| Total Liabilities | 638.00K | 14.81M | 1.58M | 272.00K | 2.25M | 1.76M |
| Stockholders Equity | 5.59M | 16.80M | 3.58M | 2.54M | 3.63M | 13.27M |
Cash Flow | ||||||
| Free Cash Flow | -6.63M | -7.04M | -8.63M | -5.72M | -8.93M | -5.61M |
| Operating Cash Flow | -6.08M | -7.00M | -8.51M | -5.72M | -8.92M | -5.61M |
| Investing Cash Flow | -556.00K | -705.00K | -118.00K | 0 | -11.00K | 0 |
| Financing Cash Flow | 7.89M | 18.35M | 8.51M | 4.33M | -528.00K | 17.54M |
Valion Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VBIO, the sentiment is Negative. The current price of 0.50 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 1.75, and below the 200-day MA of 13.87, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 21.16 is Positive, neither overbought nor oversold. The STOCH value of 23.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VBIO.
Valion Bio Risk Analysis
Valion Bio disclosed 60 risk factors in its most recent earnings report. Valion Bio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksValion Bio Peers Comparison
Overall Rating
AEMD50Neutral- VBIO46Neutral
BJDX44Neutral
MOVE44Neutral
NUWE41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AEMD | 50Neutral | $8.90M | -0.47 | -123.09% | ― | ― | 87.54% |
| VBIO | 46Neutral | $1.14M | -0.00 | -165.44% | ― | ― | ― |
| BJDX | 44Neutral | $3.14M | -0.07 | -125.01% | ― | ― | 93.91% |
| MOVE | 44Neutral | $156.50M | -0.47 | -9.67% | ― | 843.62% | 21.98% |
| NUWE | 41Neutral | $2.83M | -0.00 | -605.75% | ― | 8.36% | 88.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VBIO | Valion Bio, Inc. | 0.50 | -51.50 | -99.03% | |
| NUWE | Nuwellis, Inc. | 5.53 | -764.64 | -99.28% | |
| AEMD | Aethlon | 5.53 | -18.17 | -76.67% | |
| BBLG | Bone Biologics Corp | 0.35 | -1.35 | -79.41% | |
| MOVE | Corvex, Inc. | 5.70 | -1.85 | -24.47% | |
| BJDX | Bluejay Diagnostics, Inc. | 2.80 | -22.00 | -88.71% |
Valion Bio Corporate Events
Valion Bio Announces Series B Preferred Stock Financing
PositiveOn November 6, 2026, Valion Bio, Inc., a Delaware corporation, issued 700 Series B non-voting convertible preferred shares and warrants to purchase 21,539 common shares to 3i, LP for $700,000. The securities were sold under a private-placement exempt...
Valion Bio Executives Announce Voluntary Resignations Effective December
NegativeOn October 31, 2026, Lisa Wolf notified Valion Bio, Inc.’s Special Committee of her decision to voluntarily resign as president, chief operating officer and chief financial officer. The resignations were scheduled to become effective December 11, 202...
Valion Bio Enters Separation Agreement With Former General Counsel
PositiveOn October 27, 2026, Valion Bio notified General Counsel and Senior Vice President of Legal Affairs Melinda Lackey of the termination of her employment, effective October 30. On October 31, the company entered a separation agreement providing Lackey...
Valion Bio expands preferred equity financing through private placements
PositiveOn October 26, 2026, Valion Bio and investor 3i, LP executed a letter agreement for a further closing under their Series B financing, with 3i agreeing to purchase 50 Series B Non-Voting Convertible Preferred Shares and warrants for 1,539 common share...
Valion Bio Secures Additional Series B Preferred Financing
PositiveOn October 7, 2026, Valion Bio, Inc. entered into a third side letter with investor 3i, LP under an existing Series B Preferred Purchase Agreement initially dated April 29, 2025 and amended December 9, 2025. Under this latest arrangement, 3i agreed t...
Valion Bio Names Interim CEO Amid Governance Reshuffle
PositiveOn September 22, 2026, Valion Bio appointed board member and life sciences veteran Dean Zikria as Interim Chief Executive Officer, effective immediately, under a consulting agreement that treats him as an independent contractor and runs through Janua...
Valion Bio raises capital via new preferred financing
NeutralOn August 31, 2026, Valion Bio entered a letter agreement with investor 3i to issue additional Series B and Series C non-voting convertible preferred shares and accompanying warrants for an aggregate purchase price of about $7.7 million, adjusted for...
Valion Bio Enacts Reverse Stock Split to Maintain Listing
NeutralValion Bio, Inc., a Nasdaq-listed biotech focused on immune-modulating biologics for radiation-related and immune dysfunction conditions, is advancing lead drug Entolimod for Acute Radiation Syndrome under special FDA provisions, alongside next-gener...
Valion Bio Secures New Series B Preferred Financing
PositiveOn August 17, 2026, Valion Bio entered into a letter agreement with 3i, LP to issue 1,500 shares of Series B Non-Voting Convertible Preferred Stock at $1,000 per share and associated Series B warrants for a total of $1.5 million, under a previously e...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026